Danazol versus [d-Trp6]GnRH agonist for the management of infertility due to atypical endometriosis

Vasilis A. Tzingounis, Emmanuel Cardamakis
In: Letters in Peptide Science · 1996 · vol. 3(4) , pp. 247–251 · doi:10.1007/bf00128115 · W2073479308
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-11 ⓘ

This study found danazol and triptorelin equally effective for treating atypical endometriosis-related infertility, with triptorelin showing higher pregnancy rates than no treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-11 · read from full text ⓘ

This prospective randomized study assessed how atypical endometriosis affects fertility and compared fertility outcomes after treatment with danazol versus a [d-Trp6]GnRH agonist (triptorelin), with an untreated control group. One hundred three women (ages 21–41) were allocated to danazol 600 mg/day for 6 months (Group A), triptorelin 3.75 mg injections every 28 days for 6 months (Group B), or no treatment (Group C), and groups were comparable by infertility duration and age. More pregnancies occurred with triptorelin (65.62%) than with no treatment (20.58%), while pregnancies were not significantly different between triptorelin and danazol (54.05%); spontaneous abortion rates did not differ, and overall monthly fecundity in Group B was 0.11. The study’s reported outcomes do not show a clear advantage for danazol over the GnRH agonist and include limited statistical detail beyond the stated p-values. This paper is centrally about endometriosis — it directly evaluates danazol versus [d-Trp6]GnRH agonist for infertility due to atypical endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,205 characters · extracted from oa-doi-fallback · click to expand
Summary The aim of this study is to assess the impact of atypical endometriosis on fertility as well as the effect of treatment in endometriosis-related infertility. A prospective randomized study comparing the effects of triptorelin (Arvekap, Ipsen) and danazol (Danatrol, Winthrop) was completed recently. The 103 patients (aged 30.9±4.92, range 21–41) who finished the study were divided into three comparable (infertility duration, age) groups. Group A (n=37) received danazol (600 mg/day) for 6 months, Group B (n=32) received triptorelin (3.75 mg) injections, one every 28 days for 6 months, and Group C (n=34) did not receive any kind of treatment. More pregnancies were observed in Group B (65.62%) compared with Group C (20.58%, p=0.00012) but not compared with Group A (54.05%, p=0.05857). The overall monthly fecundity rate in Group B was 0.11, and differences concerning spontaneous abortion rates were not observed. Our results indicate that danazol and triptorelin are equally effective in the treatment of atypical endometriosis-related infertility. Similar content being viewed by others References Barlow D.M., Am. J. Obstet. Gynecol., 125 (1976) 412. Soules H.A., Malinak L.R., Bury R. and Poindexter A., Am. J. Obstet. Gynecol., 125 (1976) 412. Wallace A.M., Lees D.A.R., Roberts A.D.G. and Gray C.E., Acta Endocrinol., 107 (1984) 445. Muse K., In Wilson E.A. (Ed.) Endometriosis, Liss, New York, NY, U.S.A., 1987, p. 94. Badaway S.Z., Marshall L. and Cuenca V., Int. J. Fertil., 30 (1985) 48. Ylikorkala O., Koskimies A.I., Laatkainen T. and Penhusen A., Obstet. Gynecol., 63 (1984) 616. Brosens I.A., Koninckx P.R. and Corveleyn P.A., Br. J. Obstet. Gynaecol., 85 (1978) 246. Coutinho E.M., Am. J. Obstet. Gynecol., 144 (1982) 898. Lemay A., Maheux R., Faure N., Jean C. and Fazekas A.T.A., Fertil. Steril., 41 (1984) 863. Donnez J., Nisolle M., Clerckx F. and Casanas-Roux F., Gynecol. Endocrinol., 2 (1988) 84. Dmowski W.P. and Cohen M.R., Am. J. Obstet. Gynecol., 130 (1978) 41. Greenblatt R.B. and Tzingounis V.A., Fertil. Steril., 32 (1978) 518. Guzick D.S. and Rock J.A., Fertil. Steril., 40 (1983) 580. Butler L., Wilson E., Belisle S., Gibson M., Albrecht B., Schiff I. and Stillman R., Fertil. Steril., 41 (1984) 373. ButtramJr. V.C., Reiter P.-C. and Ward S., Fertil. Steril., 43 (1985) 353. Fedele L., Parazzini F., Radici E., Bocciolone L., Bianchi S., Bianchi C. and Candiani G.B., Am. J. Obstet. Gynecol., 166 (1992) 1345. Henzl M.R., Cirson S.L., Maghissi K., Buttram V.A., Bergvist C. and Jacobson J., New Engl. J. Med., 318 (1988) 485. Fedele L., Bianchi S., Arcaini L., Vercellini P. and Candian G.B., Am. J. Obstet. Gynecol., 161 (1989) 871. Franssen A.M.H.W., Zijlstra K.A., Kauer F.M., Rolland R. and Chadha D.R., Fertil. Steril., 51 (1989) 401. Hughes E.G., Fedorkkow D.M. and Collins J.A., Fertil. Steril., 59 (1993) 963. Jansen R.P. and Russel P., Am. J. Obstet. Gynecol., 155 (1986) 1154. Thomas E.J. and Cooke I.D., Br. Med. J., 294 (1987) 117. Brosens I.A., Acta Obstet. Gynecol. Scand., 159 (1994) 18. Petersohn L., Acta Obstet. Gynecol. Scand., 49 (1970) 331. Naples J.D., Batt R.E. and Sadigh H., Obstet. Gynecol., 57 (1981) 509. Olive D.L., Franklin R.R. and Gratkins D., J. Reprod. Med., 27 (1982) 333. Lemay A., Maheux R. and Dodin-Dewailly S., In Boutaleb Y. and Gzouli A. (Eds.) The Treatment of Endometriosis, The Parthenon Publishing Group, Casterton Hall Canforth, U.K., 1991, pp. 17–30. Tzingounis V.A., Cardamakis E., Lioutas G.P. and Pappas A.P., J. Am. Assoc. Gynecol. Laparoscopists, 2 (1995) S.54. Vernon M.S., Beard J.S., Graves K. and Wilson E.A., Fertil. Steril., 42 (1986) 801. Redwine D.B., Fertil. Steril., 47 (1987) 1062. Tzingounis, V.A. and Cardamakis, E., 4th World Congress of Endometriosis, Salvador de Bahia, Brazil, May 25–28, 1994, Abstract FC-10. Author information Authors and Affiliations Rights and permissions About this article Cite this article Tzingounis, V.A., Cardamakis, E. Danazol versus [d-Trp6]GnRH agonist for the management of infertility due to atypical endometriosis. Lett Pept Sci 3, 247–251 (1996). https://doi.org/10.1007/BF00128115 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF00128115

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK